Date: 2015-09-28
Type of information: Nomination
Compound:
Company: Nuevolution (Denmark)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 28, 2015, Nuevolution announced the appointment of MD Keith Nolop, who will support the company in a Chief Medical Officer consultancy role. Dr. Nolop has more than 25 years of drug development experience in multiple therapeutic areas, and has been the medical lead for numerous IND filings, clinical development programs and 5 marketed therapies including Zelboraf - a pioneering personalized medicine for the treatment of melanoma. Previously, he served as CMO at Plexxikon and Kite Pharma, and he had several high-level clinical research roles at CoTherix and Schering-Plough. He received his MD training at Vanderbilt University School of Medicine, TN and is board-certified in Internal Medicine and Pulmonary Medicine.
Financial terms:
Latest news:
